RESEARCH MONOGRAPH · KDC-MN-1351

Tropisetron

May 9, 2026 Kodiac biolabs Research Revised May 19, 2026 4 min read

Selective 5-HT3 receptor antagonist with alpha-7 nicotinic acetylcholine receptor partial agonism

A serotonergic indolylcarboxylate ester developed at Sandoz as a chemotherapy-induced antiemetic, distinguished from other setrons by intrinsic partial agonist activity at the alpha-7 nicotinic acetylcholine receptor and downstream cognitive, anti-inflammatory, and analgesic activity.

Abstract

Tropisetron, the indol-3-carboxylate ester of tropine and the third selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist introduced for the management of chemotherapy-induced and postoperative nausea and vomiting, is a clinically marketed antiemetic in approximately 50 jurisdictions outside the United States and a research compound of escalating interest in cognition, central nervous system inflammation, fibromyalgia, and Alzheimer's disease. Distinct from ondansetron and granisetron in pharmacology though not in marketed indication, tropisetron is a dual-mechanism agent: at the 5-HT3 ligand-gated cation channel it produces insurmountable, low-nanomolar antagonism with approximately 1000-fold selectivity over other monoamine receptors, while at the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor it acts as a potent partial agonist with low-micromolar functional activity. The alpha-7 nicotinic activity, first formally characterized by Macor et al. (2001) and subsequently extended by the Hashimoto laboratory in mouse models of phencyclidine-induced cognitive deficit and DBA/2 P50 auditory gating dysfunction, distinguishes tropisetron sharply from the other clinically marketed setrons and underwrites a research literature that now spans schizophrenia cognitive endpoints, fibromyalgia analgesia, refractory pruritus, ocular and pulmonary inflammation, postoperative neurocognitive recovery, and a Spilman et al. (2014) demonstration that tropisetron also binds the ectodomain of amyloid precursor protein at submicromolar affinity and normalizes cognition in the J20 transgenic mouse model of Alzheimer's disease at a human-equivalent oral dose of approximately 5 mg per day. Pharmacokinetics in humans are dominated by hepatic CYP2D6-mediated ring hydroxylation, producing a striking polymorphic phenotype: extensive metabolizers exhibit 5 to 8 hour plasma elimination half-life while CYP2D6 poor metabolizers extend to 30 to 40 hours. The compound is well tolerated at registered doses; principal short-term adverse events are dose-dependent constipation, headache, and transient hypertension, with rare clinically significant arrhythmia.

Mechanism of action

Dual mechanism. (1) High-affinity insurmountable antagonism at the 5-HT3 ligand-gated cation channel (Ki low nanomolar, approximately 1000-fold selectivity over other monoamine receptors), producing antiemetic effect via vagal afferent and area postrema blockade and analgesic effect via dorsal horn modulation. (2) Potent partial agonism at the homomeric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor (Ki 6.9 nM at rat brain alpha-7 sites, intrinsic activity 25-40 percent of acetylcholine maximum, EC50 low-micromolar in heterologous expression systems), producing cognitive enhancement and anti-inflammatory effects via the cholinergic anti-inflammatory pathway. (3) Tertiary binding at the ectodomain of amyloid precursor protein (Kd approximately 0.9 micromolar) promoting alpha-secretase processing and the neurotrophic sAPPalpha pathway, supporting Alzheimer-disease application.

Reported research dose ranges

Antiemetic indication: 5 mg per oral administration once daily for chemotherapy-induced or postoperative nausea and vomiting prophylaxis. Fibromyalgia indication (in jurisdictions where approved): 5 mg per oral administration once daily for 10 to 28 days. Intravenous protocol: 2 mg per day for 5 days. Schizophrenia cognitive research: 5 to 25 mg per oral administration once daily for 10 days. Alzheimer-disease research (proposed): 5 mg per oral administration once daily. CYP2D6 polymorphism is a major determinant of dose-response and adverse-event interpretation; poor metabolizers achieve 5 to 10-fold higher plasma concentrations on chronic dosing.

Selected references

  1. Macor JE, Gurley D, Lanthorn T, et al. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha-7 nicotinic receptor partial agonist. Bioorg Med Chem Lett. 2001;11(3):319-321.
  2. Hashimoto K, Iyo M, Freedman R, Stevens KE. Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of alpha-7 nicotinic acetylcholine receptors. Psychopharmacology (Berl). 2005;183(1):13-19.
  3. Hashimoto K, Fujita Y, Ishima T, Hagiwara H, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of alpha-7 nicotinic receptors. Eur Neuropsychopharmacol. 2006;16(7):500-505.
  4. Shiina A, Shirayama Y, Niitsu T, et al. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry. 2010;9:27.
  5. Zhang XY, Liu L, Liu S, et al. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry. 2012;169(9):974-981.
  6. Spilman P, Descamps O, Gorostiza O, et al. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer model. Brain Res. 2014;1551:25-44.
  7. Bredesen DE. Tropisetron and its targets in Alzheimer disease. Expert Opin Ther Targets. 2014;18(12):1379-1392.
  8. Kees F, Faerber L, Bucher M, et al. Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br J Clin Pharmacol. 2001;52(6):705-707.
  9. Kim KA, Lee HM, Joo HJ, Park JY. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. Eur J Clin Pharmacol. 2003;59(2):111-116.
  10. Faerber L, Stratz T, Brueckle W, et al. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Int J Clin Pharmacol Res. 2001;21(1):1-13.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action across three molecular targets, comprehensive pharmacokinetics with CYP2D6 polymorphism analysis, indication-by-indication clinical evidence base (antiemetic, fibromyalgia, schizophrenia cognitive, Alzheimer disease, tinnitus, inflammatory), reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, adverse event signal, and a structured comparative assessment of five alpha-7 nicotinic acetylcholine receptor candidates (encenicline, bradanicline, AVL-3288, GTS-21, PHA-543613) judged against five competency standards. Embedded inline below; download for offline reading.

KDC-MN-1351 Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Adjacent monographs